|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Re-evaluation of oral contraceptive classifications. |
| In: Benefits and risks of OCs: a current perspective. Symposium monograph, |
| [compiled by] Health Learning Systems Little Falls, New Jersey, Health Learning |
| Many pharmaceuticals, including oral contraceptives (OCs), are often classified by "generations" based on the time of |
| introduction of new formulations. In the case of combined OCs, such a classification system is of little clinical |
| utility given the need to address the differing evolution of the estrogen and progestin components. Over the past 30 |
| years, the estrogen dose of OCs has progressively decreased. Although the progestin dose also has decreased, |
| several types of progestins have been used. These progestins can be classified as either estranes or the newer, |
| biologically more potent gonanes. Desogestrel, gestodene, and norgestimate inhibit ovulation at lower doses than |
| the estranes and have lower androgenicity than levonorgestrel or the estranes. Although these low-androgenic |
| progestins were introduced at approximately the same time ("third generation"), there are subtle differences in |
| chemical structure, metabolism, androgenicity, and safety profile. Since most OCs in use today contain less than 50 |
| mcg of ethinyl estradiol, classification of OCs relative to their progestin component in terms of level of androgenic |
| activity may be more relevant. (PubHealth.info Document ID: CONT2T 1034-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Re-evaluation of oral contraceptive classifications.", is(are) |
| Burkman RT. The source of this article is "In: Benefits and risks of OCs: a current perspective. Symposium |
| monograph, [compiled by] Health Learning Systems Little Falls, New Jersey, Health Learning Systems, 1997. :24-8.". |
| This article was published in 1997 in English language(s). (PubHealth.info® Document ID: CONT2T 1034-06. All |
| rights reserved with PubHealth.info) PIN: 6034 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |